Frequently Asked Questions


ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers. An improvement in hemostasis has not been established. Continued approval for this indication may be contingent upon the results of studies that demonstrate an improvement in hemostasis in patients.*1
*ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban or rivaroxaban.
FXa inhibitor–related major bleeds can occur in several sites:2-4
- Intracranial Hemorrhage — intracerebral, subdural, subarachnoid
- Bleeding at a Critical Site — intraocular, pericardial, intraspinal, intra-articular
- Major Bleeding with Hemodynamic Instability — gastrointestinal, retroperitoneal, genitourinary tract bleed
- Major Trauma — blunt or penetrating injury


*ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban or rivaroxaban.
Learn MoreANDEXXA provides rapid, specific reversal for apixaban- or rivaroxaban-related life-threatening or uncontrolled bleeds in just 2 minutes following an initial bolus and sustained throughout a 2-hour IV infusion.1
ANNEXA-A and ANNEXXA-R were two Phase 3 studies designed to establish the efficacy and safety of ANDEXXA for the reversal of anticoagulation with apixaban or rivaroxaban in older, healthy volunteers vs placebo. The primary endpoint of both studies was mean percent change in anti-FXa activity, from baseline to nadir, for the low-dose and high-dose regimens of bolus followed by continuous infusion. In ANNEXA-A and ANNEXA-R, 23/31 and 26/39 patients received ANDEXXA respectively.1
ANNEXA-A and ANNEXA-R were two Phase 3 prospective, randomized, placebo-controlled studies conducted in healthy volunteers (50-73 years old)
- ANNEXA-A (N=31) included only apixaban-treated subjects
- ANNEXA-R (N=39) included only rivaroxaban-treated subjects
ANNEXA-4 was a Phase 3b/4 multinational, prospective, single-arm, open-label study of ANDEXXA patients taking FXa inhibitors who presented with acute major bleeding (N=352)
Dose* | Initial IV Bolus | Follow-On IV Infusion | Total Number of 200 mg Vials |
---|---|---|---|
Low Dose | 400 mg at a target rate of 30 mg/min | 4 mg/min for up to 120 minutes (480 mg) | 5 (2 vials bolus + 3 vials infusion) |
High Dose | 800 mg at a target rate of 30 mg/min | 8 mg/min for up to 120 minutes (960 mg) | 9 (4 vials bolus + 5 vials infusion) |
Drug FXa Inhibitor |
Dose Strength of Last Dose |
Time Since Last Dose Taken |
|
---|---|---|---|
<8 Hours or Unknown | ≥8 Hours | ||
ELIQUIS® (apixaban) |
≤5mg | Low Dose | Low Dose |
>5 mg or Unknown | High Dose | Low Dose | |
XARELTO® (rivaroxban) |
≤10 mg | Low Dose | Low Dose |
>10 mg or Unknown | High Dose | Low Dose |
Carton NDC Number: 69853-0102-1
Carton Configuration: 4 single-use vials per carton, each vial containing 200 mg
Vial Cap Color: Vials have a red, flip-off cap

Medicare (Part A) will reimburse eligible claims for administration of ANDEXXA in hospital inpatient settings under ICD-10-PCS Codes XW03372 and XW04372.8
Medicare (Part B): Effective July 1, 2020, the Centers for Medicare and Medicaid Services (CMS) has granted ANDEXXA its permanent J-code (J7169), facilitating reimbursement in all hospital outpatient departments and freestanding emergency facilities in the United States.9
In addition to the MS-DRG payment, Medicare New Technology Add-on Payment (NTAP) may facilitate an additional payment equal to the lesser of (i) 65% of the cost of ANDEXXA being directly paid for in addition to the MS-DRG payment, or (ii) 65% of the amount by which the costs of the case exceed the standard MS-DRG payment.8
The specifics of coverage may vary by payer and can be specific to the patient’s unique plan. Please reference the individual patient’s plan to determine applicable coverage requirements.
ANDEXXA is currently available through these distributors:
- ASD Healthcare®
- BioCare SD®
- CardinalHealth™
- FFF Enterprises
- McKesson
- Prodigy Health
Additional questions?
For additional questions, please call 1-866-777-5947.